Boehringer Ingelheim Introduces Bultavo 3 Vaccine Against Bluetongue Virus Serotype 3 for Sheep and Cattle
Shots:
- Boehringer Ingelheim has reported the launch of the Bultavo 3 vaccine against bluetongue virus (BTV) serotype 3 expanding its ruminant vaccine portfolio
- Bultavo 3 is an inactivated vaccine (adjuvanted with aluminum hydroxide and saponine) administered subcutaneously in sheep (1 shot) and intramuscularly in cattle (2 shots, 3wks. apart) for preventing mortality and clinical signs of BTV-3
- Additionally, the company partnered with Bioveta for the development of Bultavo 3 which will be available in affected countries (Netherlands, Belgium and Germany) starting from the end of May 2024, with emergency licensing in the Netherlands
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Collaborates with Walgreens to Improve Clinical Trials Access
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
